Cigna Group (CI) last closed at $274.47, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for CI, covered for search and blurred for visitors.
Performance
1D-0.73%
5D+5.11%
1M+11.19%
3M+6.32%
6M+10.80%
1Y-0.80%
5Y+52.59%
Financials
Over the latest four reported periods ending June 30, 2026, Cigna Group reported revenue of $282.38 billion.
The prior window totaled $262.02 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $10.28 billion.
Free cash flow in the latest window was $10.28 billion.
These amounts are taken from Cigna Group's SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE 3.9% (12 of 100). Leverage: D/E 0.68× (73 of 100). Cash generation: FCF margin 3.6% (7 of 100). Net margin: 2.3% (6 of 100). Liquidity: Current 0.85× (42 of 100).
Finorify's notes from those filings, written September 21, 2026: Scale and Specialty Pharmacy Leadership via Evernorth. Through its Evernorth Health Services division—anchored by Express Scripts and Accredo—Cigna commands massive scale in pharmacy benefit management (PBM) and specialty pharmacy dispensing. This purchasing volume enables superior pharmaceutical manufacturer negotiations, efficient distribution of complex high-cost therapies, and extensive network economics that are difficult for smaller competitors to replicate. Capital-Efficient, Fee-Based Commercial Franchise. Cigna possesses an entrenched market position with large corporate employers, primarily through self-funded administrative services only (ASO) plans. This fee-based model insulates a significant portion of Cigna's earnings from direct underwriting and medical loss volatility while providing high-margin, recurring cash flows and strong client retention. Integrated Healthcare and Health Services Ecosystem. The seamless integration of Cigna Healthcare (medical benefits) with Evernorth (pharmacy, behavioral health, and care delivery) enables coordinated clinical management. By aligning medical and pharmacy data, Cigna can effectively lower total cost of care for clients, driving differentiated value propositions and cross-selling opportunities across its enterprise. Regulatory and Legislative Scrutiny on PBM Business Models. Evernorth faces intense scrutiny from federal and state lawmakers and regulatory bodies, including the FTC, regarding pharmacy benefit management practices, rebate structures, and spread pricing. Potential legislation mandating transparency or restricting traditional PBM compensation models could structurally compress profit margins. Medical Cost Trend Inflation and High-Cost Drug Utilization. Unanticipated surges in healthcare utilization, medical cost inflation, and the rapid adoption of expensive new therapies (such as GLP-1s and gene therapies) can pressure medical loss ratios within risk-bearing commercial plans and challenge the cost-containment guarantees offered to self-insured clients. Key Client Concentration and Recontracting Risk. A meaningful share of Evernorth's pharmacy volumes and revenues is derived from large health plan partners, government accounts, and major enterprise clients. The loss, contract renegotiation on less favorable terms, or insourcing of pharmacy services by major health plan customers represents a substantial operational risk.
Cash Flow
Margins
Valuation
P/E (TTM)
11.36
Insights
Advantage
Scale and Specialty Pharmacy Leadership via Evernorth
Through its Evernorth Health Services division—anchored by Express Scripts and Accredo—Cigna commands massive scale in pharmacy benefit management (PBM) and specialty pharmacy dispensing. This purchasing volume enables superior pharmaceutical manufacturer negotiations, efficient distribution of complex high-cost therapies, and extensive network economics that are difficult for smaller competitors to replicate.
Advantage
Capital-Efficient, Fee-Based Commercial Franchise
Cigna possesses an entrenched market position with large corporate employers, primarily through self-funded administrative services only (ASO) plans. This fee-based model insulates a significant portion of Cigna's earnings from direct underwriting and medical loss volatility while providing high-margin, recurring cash flows and strong client retention.
Advantage
Integrated Healthcare and Health Services Ecosystem
The seamless integration of Cigna Healthcare (medical benefits) with Evernorth (pharmacy, behavioral health, and care delivery) enables coordinated clinical management. By aligning medical and pharmacy data, Cigna can effectively lower total cost of care for clients, driving differentiated value propositions and cross-selling opportunities across its enterprise.
Risk
Regulatory and Legislative Scrutiny on PBM Business Models
Evernorth faces intense scrutiny from federal and state lawmakers and regulatory bodies, including the FTC, regarding pharmacy benefit management practices, rebate structures, and spread pricing. Potential legislation mandating transparency or restricting traditional PBM compensation models could structurally compress profit margins.
Risk
Medical Cost Trend Inflation and High-Cost Drug Utilization
Unanticipated surges in healthcare utilization, medical cost inflation, and the rapid adoption of expensive new therapies (such as GLP-1s and gene therapies) can pressure medical loss ratios within risk-bearing commercial plans and challenge the cost-containment guarantees offered to self-insured clients.
Risk
Key Client Concentration and Recontracting Risk
A meaningful share of Evernorth's pharmacy volumes and revenues is derived from large health plan partners, government accounts, and major enterprise clients. The loss, contract renegotiation on less favorable terms, or insourcing of pharmacy services by major health plan customers represents a substantial operational risk.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.